North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19

Affiliations

¹ From the Department of Medicine, University of California San Francisco, San Francisco, CA.
² Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
³ Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA.
⁴ Department of Medicine, Stanford University Medical Center, Palo Alto, CA.
⁵ Department of Medicine, University of Utah Health, Salt Lake City, UT.
⁶ Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
⁷ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
⁸ Department of Radiology, University of California San Francisco, San Francisco.
⁹ NorCal CarciNET Community, Ripon, CA.
¹⁰ Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, IA.

Practice Guideline

Emily K Bergsland et al. Pancreas. 2020 Jul.

. 2020 Jul;49(6):723-728.

doi: 10.1097/MPA.0000000000001561.

¹ From the Department of Medicine, University of California San Francisco, San Francisco, CA.
² Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
³ Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA.
⁴ Department of Medicine, Stanford University Medical Center, Palo Alto, CA.
⁵ Department of Medicine, University of Utah Health, Salt Lake City, UT.
⁶ Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
⁷ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
⁸ Department of Radiology, University of California San Francisco, San Francisco.
⁹ NorCal CarciNET Community, Ripon, CA.
¹⁰ Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, IA.

No abstract available

Conflict of interest statement

The authors declare no conflict of interest.

1. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine Tumors. N Engl J Med. 2017;376:125–135. - PMC - PubMed
1. Thapa P, Ranade R, Ostwal V, et al. Performance of 177Lu-DOTATATE–based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Nucl Med Commun. 2016;37:1030–1037. - PubMed
1. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617–4624. - PubMed
1. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–977. - PMC - PubMed
1. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523. - PMC - PubMed